Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bethanidine elimination from plasma.

C N Corder

    Journal of Clinical Pharmacology
    |August 1, 1979
    PubMed
    Summary

    This study investigated how the body processes bethanidine in hypertensive patients with normal versus impaired kidney function. Pharmacokinetic constants were similar, indicating comparable drug processing despite varying renal function.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Superior oblique tendon resection or inferior oblique muscle recession in vertical deviations.

    American journal of therapeutics·1999
    Same author

    Effect of probucol therapy on plasma fatty acid composition during postprandial lipemia in hypertriglyceridemia.

    American journal of therapeutics·1997
    Same author

    Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).

    Arteriosclerosis and thrombosis : a journal of vascular biology·1994
    Same author

    Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group.

    Pharmacotherapy·1994
    Same author

    Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group I.

    The American journal of cardiology·1993
    Same author

    Lipid peroxide levels in type II hyperlipoproteinemic subjects.

    Artery·1993

    Area of Science:

    • Pharmacology
    • Nephrology
    • Clinical Pharmacy

    Background:

    • Hypertension is a prevalent condition often requiring pharmacologic management.
    • Renal function significantly influences drug pharmacokinetics.
    • Understanding bethanidine's behavior in renal impairment is crucial for safe and effective dosing.

    Purpose of the Study:

    • To characterize the pharmacokinetics of bethanidine in hypertensive patients.
    • To compare bethanidine's elimination half-time and distribution in patients with normal versus impaired renal function.
    • To assess the impact of renal impairment on bethanidine's pharmacokinetic profile.

    Main Methods:

    • Intravenous administration of bethanidine (0.7 mumole/kg) to two groups of hypertensive patients: normal renal function (n=6) and renal impairment (n=5).
    • Serial blood sampling for plasma bethanidine concentration measurement.
    • Analysis using a three-compartment exponential open-model system.

    Main Results:

    • The rapid elimination phase (beta) half-time was 3.4 hours in normal subjects and 16.4 hours in renal impairment.
    • Terminal elimination phases were 90 hours (normals) and 70 hours (impaired).
    • Volume of distribution at pseudoequilibrium was 2.8 L/kg (normals) and 1.6 L/kg (impaired), suggesting tissue sequestration.

    Conclusions:

    • Despite prolonged elimination phases and altered distribution in renal impairment, overall pharmacokinetic constants for bethanidine were similar between normal and impaired renal function groups.
    • Bethanidine appears to be processed similarly by the body regardless of renal function, though tissue sequestration is notable.
    • Further studies may be warranted to fully elucidate the clinical implications of these findings.

    Related Experiment Videos